Clinical Pearls for Treating Patients With Metastatic TNBC
Hope Rugo, MD, provides insights on best practices for managing metastatic TNBC in community settings.
Hope Rugo, MD: The real clinical pearls we need in this situation is to be sure to measure for PD-L1–positivity. Think about checkpoint inhibitors in the metastatic setting. Carefully choose the chemotherapy based on the patient’s own history of response to chemotherapy agents. Use nab-paclitaxel preferentially rather than paclitaxel if you’re using a taxane. Monitor carefully for immune toxicity. Treat early and educate our patients about these toxicities, because you can get almost any patient through toxicity if you recognize it early and treat early. It’s clear that if you don’t, the toxicities can become life-threatening. With the use of checkpoint inhibitors, we’ve seen real improvements in our patients with triple-negative breast cancer.
The future is trying to move these treatments earlier. There are exciting data from the early-stage setting we talked about, but also looking at new ways to give checkpoint inhibitors in the metastatic setting. Giving induction with checkpoint inhibitors or chemotherapy to try to jump-start the immune response. Using different targeted agents with immune checkpoint inhibitors, antibody-drug conjugates, or radiation therapy are all areas that are being tested. I mentioned PARP inhibitors earlier. It’s certainly an exciting time, when we have immune therapies that are effective in our patients with triple-negative breast cancer. But this only affects about 40% of patients in the metastatic setting who are at least a year from their recurrence, and about 38% of patients who are 6 months or farther out. We need better solutions for our patients with the most highly resistant disease and for those patients with PD-L1–negative disease.
Thank you for your attention.
Transcript edited for clarity.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
